FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2755743522> ?p ?o ?g. }

• W2755743522 endingPage "1197" @default.
• W2755743522 startingPage "1189" @default.
• W2755743522 abstract "Abstract Introduction Varenicline reduces smoking satisfaction during the pre-cessation run-in period, which may contribute to extinction of cravings and smoking behavior. Research indicates that efficacy is enhanced when the run-in period is increased from 1 to 4 weeks, providing a longer extinction opportunity. We hypothesized that efficacy could be further enhanced by harnessing basic and applied research on extinction. We developed a pre-cessation extinction-facilitating intervention and tested its feasibility in a pilot trial. Methods The facilitated extinction (FE) intervention comprised brief counseling and workbook-recommending strategies to maximize extinction processes during the run-in, including instructions to smoke at a normal rate across contexts and cues, and use of an extinction cue to enhance generalization. Participants were randomly assigned to one of three varenicline interventions: standard (1-week run-in), extended (4-week run-in), and extended + FE. Interventions were delivered prior to the target quit date (TQD). Assessments were conducted in weeks 1 and 4 pre-TQD and 1 and 3 months post-TQD, with focus on feasibility indices. Results Recruitment and retention goals were met (N = 58). Treatment satisfaction was high across groups. The majority of FE participants adhered to instructions and maintained their usual smoking rate during the run-in period. Greater decreases in craving and smoking satisfaction were observed among participants in both extended groups versus the standard group (p &lt; .005). Conclusions Feasibility was demonstrated. Participants adhered to the FE intervention, thereby optimizing the number and variety of extinction trials. Findings support testing the novel FE smoking cessation intervention in a fully powered trial. Implications This study expands the research on the clinical benefits of extending the pre-cessation run-in period of varenicline. It introduces the hypothesis that further benefit might be achieved by translating basic behavioral research, as well as cue-exposure research and therapy for other disorders, to improve the extinction and generalization processes thought to underlie much of varenicline’s effect. A FE intervention was developed and found acceptable to smokers and feasible to implement in a research setting. The study sets the stage for a subsequent randomized controlled trial." @default.
• W2755743522 created "2017-09-25" @default.
• W2755743522 creator A5000114238 @default.
• W2755743522 creator A5012422908 @default.
• W2755743522 creator A5012451000 @default.
• W2755743522 creator A5013002424 @default.
• W2755743522 creator A5030821261 @default.
• W2755743522 creator A5035969916 @default.
• W2755743522 creator A5042697152 @default.
• W2755743522 creator A5049376698 @default.
• W2755743522 creator A5053563608 @default.
• W2755743522 creator A5054915197 @default.
• W2755743522 creator A5059942593 @default.
• W2755743522 date "2017-09-12" @default.
• W2755743522 modified "2023-09-29" @default.
• W2755743522 title "Facilitated Extinction Training to Improve Pharmacotherapy for Smoking Cessation: A Pilot Feasibility Trial" @default.
• W2755743522 cites W1549904073 @default.
• W2755743522 cites W1964788877 @default.
• W2755743522 cites W1969169809 @default.
• W2755743522 cites W1970885260 @default.
• W2755743522 cites W1973607893 @default.
• W2755743522 cites W1980307808 @default.
• W2755743522 cites W1990531738 @default.
• W2755743522 cites W1997522372 @default.
• W2755743522 cites W2003078192 @default.
• W2755743522 cites W2013436152 @default.
• W2755743522 cites W2016065484 @default.
• W2755743522 cites W2026845717 @default.
• W2755743522 cites W2028758200 @default.
• W2755743522 cites W2031163840 @default.
• W2755743522 cites W2035805507 @default.
• W2755743522 cites W2044625851 @default.
• W2755743522 cites W2062114034 @default.
• W2755743522 cites W2065107893 @default.
• W2755743522 cites W2069559297 @default.
• W2755743522 cites W2070192651 @default.
• W2755743522 cites W2084289344 @default.
• W2755743522 cites W2085618103 @default.
• W2755743522 cites W2107200746 @default.
• W2755743522 cites W2113308458 @default.
• W2755743522 cites W2117389430 @default.
• W2755743522 cites W2118061336 @default.
• W2755743522 cites W2130967235 @default.
• W2755743522 cites W2137549318 @default.
• W2755743522 cites W2141810434 @default.
• W2755743522 cites W2141833123 @default.
• W2755743522 cites W2149818961 @default.
• W2755743522 cites W2164386461 @default.
• W2755743522 cites W2171937180 @default.
• W2755743522 cites W2491140218 @default.
• W2755743522 cites W4250752854 @default.
• W2755743522 cites W4254962035 @default.
• W2755743522 cites W4296148892 @default.
• W2755743522 doi "https://doi.org/10.1093/ntr/ntx203" @default.
• W2755743522 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7868958" @default.
• W2755743522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29059409" @default.
• W2755743522 hasPublicationYear "2017" @default.
• W2755743522 type Work @default.
• W2755743522 sameAs 2755743522 @default.
• W2755743522 citedByCount "9" @default.
• W2755743522 countsByYear W27557435222018 @default.
• W2755743522 countsByYear W27557435222019 @default.
• W2755743522 countsByYear W27557435222020 @default.
• W2755743522 countsByYear W27557435222021 @default.
• W2755743522 countsByYear W27557435222022 @default.
• W2755743522 countsByYear W27557435222023 @default.
• W2755743522 crossrefType "journal-article" @default.
• W2755743522 hasAuthorship W2755743522A5000114238 @default.
• W2755743522 hasAuthorship W2755743522A5012422908 @default.
• W2755743522 hasAuthorship W2755743522A5012451000 @default.
• W2755743522 hasAuthorship W2755743522A5013002424 @default.
• W2755743522 hasAuthorship W2755743522A5030821261 @default.
• W2755743522 hasAuthorship W2755743522A5035969916 @default.
• W2755743522 hasAuthorship W2755743522A5042697152 @default.
• W2755743522 hasAuthorship W2755743522A5049376698 @default.
• W2755743522 hasAuthorship W2755743522A5053563608 @default.
• W2755743522 hasAuthorship W2755743522A5054915197 @default.
• W2755743522 hasAuthorship W2755743522A5059942593 @default.
• W2755743522 hasBestOaLocation W27557435222 @default.
• W2755743522 hasConcept C101991246 @default.
• W2755743522 hasConcept C118552586 @default.
• W2755743522 hasConcept C126322002 @default.
• W2755743522 hasConcept C142724271 @default.
• W2755743522 hasConcept C151730666 @default.
• W2755743522 hasConcept C15744967 @default.
• W2755743522 hasConcept C168563851 @default.
• W2755743522 hasConcept C27415008 @default.
• W2755743522 hasConcept C2777053506 @default.
• W2755743522 hasConcept C2777843972 @default.
• W2755743522 hasConcept C2779541405 @default.
• W2755743522 hasConcept C2780665704 @default.
• W2755743522 hasConcept C2780687700 @default.
• W2755743522 hasConcept C2781089641 @default.
• W2755743522 hasConcept C38652104 @default.
• W2755743522 hasConcept C41008148 @default.
• W2755743522 hasConcept C48856860 @default.
• W2755743522 hasConcept C70410870 @default.
• W2755743522 hasConcept C71924100 @default.

• next